JP2022504596A5 - - Google Patents

Info

Publication number
JP2022504596A5
JP2022504596A5 JP2021519698A JP2021519698A JP2022504596A5 JP 2022504596 A5 JP2022504596 A5 JP 2022504596A5 JP 2021519698 A JP2021519698 A JP 2021519698A JP 2021519698 A JP2021519698 A JP 2021519698A JP 2022504596 A5 JP2022504596 A5 JP 2022504596A5
Authority
JP
Japan
Prior art keywords
sequence
γglu
ntstc
isolated polypeptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021519698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504596A (ja
JP7636321B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/055696 external-priority patent/WO2020077129A1/en
Publication of JP2022504596A publication Critical patent/JP2022504596A/ja
Publication of JP2022504596A5 publication Critical patent/JP2022504596A5/ja
Priority to JP2024155106A priority Critical patent/JP2025000663A/ja
Application granted granted Critical
Publication of JP7636321B2 publication Critical patent/JP7636321B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021519698A 2018-10-11 2019-10-10 ヒトアミリンアナログペプチド及び使用方法 Active JP7636321B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024155106A JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862744236P 2018-10-11 2018-10-11
US62/744,236 2018-10-11
PCT/US2019/055696 WO2020077129A1 (en) 2018-10-11 2019-10-10 Human amylin analog polypeptides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024155106A Division JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Publications (3)

Publication Number Publication Date
JP2022504596A JP2022504596A (ja) 2022-01-13
JP2022504596A5 true JP2022504596A5 (https=) 2022-10-19
JP7636321B2 JP7636321B2 (ja) 2025-02-26

Family

ID=68393080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519698A Active JP7636321B2 (ja) 2018-10-11 2019-10-10 ヒトアミリンアナログペプチド及び使用方法
JP2024155106A Pending JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024155106A Pending JP2025000663A (ja) 2018-10-11 2024-09-09 ヒトアミリンアナログペプチド及び使用方法

Country Status (13)

Country Link
US (2) US12018059B2 (https=)
EP (1) EP3864031A1 (https=)
JP (2) JP7636321B2 (https=)
KR (1) KR102911883B1 (https=)
CN (2) CN113195524A (https=)
AR (1) AR116632A1 (https=)
AU (2) AU2019357621B2 (https=)
BR (1) BR112021006823A2 (https=)
IL (2) IL282079B2 (https=)
MX (1) MX2021004185A (https=)
SG (1) SG11202103586UA (https=)
TW (1) TW202028228A (https=)
WO (1) WO2020077129A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115968376A (zh) * 2020-04-17 2023-04-14 I2O治疗公司 长效胰高血糖素受体选择性肽和使用方法
EP4138780A4 (en) * 2020-04-20 2024-05-15 I2O Therapeutics, Inc. Use of human amylin analog polypeptides for providing superior glycemic control to type 1 diabetics
FI4021929T3 (fi) 2020-09-24 2023-06-14 Gubra Aps HAM15-52-analogeja, joilla on parannettu teho amyliinireseptoriin (HAMY3R)
CR20230311A (es) * 2020-12-16 2023-09-01 Medimmune Ltd Polipéptidos y usos de los mismos
TWI815327B (zh) 2021-03-03 2023-09-11 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
CN113880935B (zh) * 2021-10-25 2022-08-26 浙江肽昇生物医药有限公司 一种索马鲁肽全保护肽树脂的制备方法、一种索马鲁肽制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5321008A (en) 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
RO117259B1 (ro) 1993-08-09 2001-12-28 Biomeasure Inc. Derivaţi peptidici, terapeutici
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
NZ331186A (en) 1996-02-02 2000-04-28 Alza Corp Osmotically driven sustained delivery drug delivery capsule
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1623099A (en) 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
KR100568917B1 (ko) 1997-12-30 2006-04-07 알자 코포레이션 멤브레인 플러그를 갖는 익제 전달장치
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
CZ295044B6 (cs) 1998-12-07 2005-05-18 Societe De Conseils De Recherches Et D'application Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující
EP1140014B1 (en) 1998-12-31 2003-03-19 Alza Corporation Osmotic delivery system having space efficient piston
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
BR0010750A (pt) 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
ES2248156T3 (es) 1999-12-21 2006-03-16 Alza Corporation Valvula para dispositivos osmoticos.
CN103356996A (zh) 2000-05-19 2013-10-23 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
JP4716641B2 (ja) 2000-06-16 2011-07-06 イーライ リリー アンド カンパニー グルカゴン様ペプチド−１類似体
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
AU2002308706A1 (en) 2001-06-01 2002-12-16 Eli Lilly And Company Glp-1 formulations with protracted time action
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
AU2002322403A1 (en) 2001-08-23 2003-03-10 Eli Lilly And Company Glucagon-like peptide-1 analogs
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
DE60317225T2 (de) 2002-06-26 2008-05-29 Intarcia Therapeutics, Inc., Emeryville Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
WO2004037168A2 (en) 2002-10-18 2004-05-06 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
DE602004012081T2 (de) 2003-03-31 2009-03-19 Intarcia Therapeutics, Inc., Emeryville Osmotische pumpe mit mitteln zum ableiten des innendrucks
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
ES2662501T3 (es) * 2008-10-21 2018-04-06 Novo Nordisk A/S Derivados de amilina
ES2622877T3 (es) 2009-01-22 2017-07-07 Keybioscience Ag Tratamiento para la obesidad
CA2755068C (en) 2009-03-12 2018-11-06 Keybioscience Ag Treatment of diabetes and metabolic syndrome
CN102947335B (zh) 2010-04-15 2018-11-06 基因泰克公司 抗多聚遍在蛋白抗体及使用方法
EP2714069A4 (en) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
JP6121992B2 (ja) 2011-06-10 2017-04-26 ノヴォ ノルディスク アー／エス ポリペプチド
ES2640285T3 (es) 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
ES2741507T3 (es) 2014-04-07 2020-02-11 Novo Nordisk As Compuestos de glp-1 acilados doblemente
WO2016034604A1 (en) 2014-09-04 2016-03-10 Novo Nordisk A/S Novel amylin and calcitonin receptor agonist
BR112017019378A2 (pt) 2015-03-18 2019-02-19 Zealand Pharma A/S análogos de amilina
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues

Similar Documents

Publication Publication Date Title
JP2022504596A5 (https=)
AU677792B2 (en) New aminoacid derivates, process for producing the same and pharmaceutical compositions containing these compounds
JP3266311B2 (ja) 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
JP6334399B2 (ja) 自己組織化ペプチド誘導体の製造方法
HRP950276A2 (en) New amino acid derivatives, process for their preparation and pharmaceutical compounds (ii) containing such compounds
AU2011322618B2 (en) Process for the manufacture of degarelix and its intermediates
MXPA96005128A (en) New derivatives of amino acids, procedures for their preparation and pharmaceutical compositions that contain these compounds
AU2016353547B2 (en) Cyclic peptides targeting α4β7 integrin
CN113816990B (zh) 修饰的氨基酸及其在adc中的应用
RU2012105355A (ru) Производное аналога glp-1 или его фармацевтически приемлемые соли и их применение
RU2008100238A (ru) Соединения оксинтомодулина, фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
EP0766683A1 (en) Novel substituted purinyl derivatives with immunomodulating activity
IE50571B1 (en) Novel polypeptides,processes for their production,pharmaceutical compositions comprising said polypeptides and their use
NZ503061A (en) Cyclic tetrapeptide derivatives and use as anti-cancer agents
CN105683156A (zh) 含有肽修饰剂的氨基二酸
KR20110022594A (ko) 신규한 이중 표적화 항종양성 접합체
US11168114B2 (en) Process for the manufacture of degarelix and its intermediates
JPH06504055A (ja) ヘキサーおよびヘプタペプチドのアナフィラトキシン受容体リガンド
JP2024502740A5 (https=)
JPS59170051A (ja) 薬理活性を有するトリペプチド誘導体
CN106279357A (zh) 双[(乙酰-Lys(AA)-OBzl)吲哚]乙烷,其制备,活性和应用
TW434261B (en) Motilin-like polypeptides with gastrointestinal motor stimulating activity
ES2275460T3 (es) Dipeptidos que contienen ciclopentano-beta-aminoacidos.
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease
JP2014501750A5 (https=)